Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $172.3 million.

  • Corcept Therapeutics' Total Current Liabilities rose 3648.43% to $172.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.3 million, marking a year-over-year increase of 3648.43%. This contributed to the annual value of $140.8 million for FY2024, which is 3470.46% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Total Current Liabilities of $172.3 million as of Q3 2025, which was up 3648.43% from $144.7 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Total Current Liabilities peaked at $172.3 million during Q3 2025, and registered a low of $40.6 million during Q1 2021.
  • In the last 5 years, Corcept Therapeutics' Total Current Liabilities had a median value of $93.1 million in 2023 and averaged $91.2 million.
  • As far as peak fluctuations go, Corcept Therapeutics' Total Current Liabilities rose by 9.9% in 2021, and later soared by 12965.44% in 2023.
  • Corcept Therapeutics' Total Current Liabilities (Quarter) stood at $47.5 million in 2021, then soared by 52.48% to $72.5 million in 2022, then skyrocketed by 44.16% to $104.5 million in 2023, then skyrocketed by 34.7% to $140.8 million in 2024, then grew by 22.37% to $172.3 million in 2025.
  • Its last three reported values are $172.3 million in Q3 2025, $144.7 million for Q2 2025, and $143.1 million during Q1 2025.